for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

MeiraGTx Holdings PLC

MGTX.O

Latest Trade

--

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

--

 - 

--

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
--
Open
--
Volume
--
3M AVG Volume
3.69
Today's High
--
Today's Low
--
52 Week High
--
52 Week Low
--
Shares Out (MIL)
36.57
Market Cap (MIL)
776.78
Forward P/E
-10.48
Dividend (Yield %)
--

Next Event

MeiraGTx Holdings plc - Special Call

Latest Developments

More

Meiragtx Holdings PLC - As Of September 30, 2019, Meiragtx Had Cash And Cash Equivalents Of Approximately $253.3 Million

Meiragtx Holdings Q3 Loss Per Share $0.30

MeiraGTx Reports Q2 Loss Per Share $0.63

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About MeiraGTx Holdings PLC

MeiraGTx Holdings plc is a clinical-stage therapy company. The Company develops gene therapy treatments for a range of inherited and acquired disorders. It is focused on developing therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia, radiation treatment for head and neck cancers and neurodegenerative diseases, such as amyothrophic lateral sclerosis (ALS). It is also developing transformative technology to enable the use of small molecules to turn gene therapy product candidates on and off. It is focused on three areas of unmet medical needs, including inherited retinal diseases, severe forms of xerostomia and neurodegenerative diseases. Its product candidates include AAV-CNGB3, AAV-CNGA3, AAV-RPGR, AAV-RPE65, A006, AAV-AQP1 and AAV-UPF1.

Industry

Biotechnology & Drugs

Contact Info

450 E 29th St Fl 15

+1.646.8607983

http://meiragtx.com/

Executive Leadership

Keith R. Harris

Independent Chairman of the Board

Alexandria Forbes

President, Chief Executive Officer, Director

Richard Giroux

Chief Financial Officer, Chief Operating Officer

Bruce Gottlieb

General Counsel, Secretary

Stuart Naylor

Chief Development Officer

Key Stats

2.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-4.470

2019(E)

-2.027
Price To Earnings (TTM)
--
Price To Sales (TTM)
122.34
Price To Book (MRQ)
3.99
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-37.48
Return on Equity (TTM)
-33.25

Latest News

Latest News

Pfizer, Novartis lead $2 billion spending spree on gene therapy production

Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control production of the world's priciest medicines.

FOCUS-Pfizer, Novartis lead pharma spending spree on gene therapy production

Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control production of the world's priciest medicines.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up